Zoetis Inc.
Zoetis Inc. ZTS Peers
See (ZTS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZTS | $150.90 | +1.55% | 65.6B | 26.41 | $5.58 | +1.31% |
| TAK | $14.56 | +0.87% | 45.6B | 62.80 | $0.23 | +4.07% |
| HLN | $9.62 | +0.21% | 42.8B | 22.13 | $0.43 | +1.76% |
| TEVA | $16.29 | +1.40% | 18.7B | -14.18 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $133.09 | +0.81% | 13B | 44.69 | $2.95 | N/A |
| RDY | $14.45 | -0.24% | 12.1B | 18.43 | $0.79 | +0.66% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.23 | +3.89% | 10.4B | -2.80 | -$3.18 | +5.38% |
| ELAN | $14.98 | +1.32% | 7.3B | 19.55 | $0.75 | N/A |
Stock Comparison
ZTS vs TAK Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TAK has a market cap of 45.6B. Regarding current trading prices, ZTS is priced at $150.90, while TAK trades at $14.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TAK's P/E ratio is 62.80. In terms of profitability, ZTS's ROE is +0.51%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ZTS is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs HLN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, HLN has a market cap of 42.8B. Regarding current trading prices, ZTS is priced at $150.90, while HLN trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas HLN's P/E ratio is 22.13. In terms of profitability, ZTS's ROE is +0.51%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ZTS is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs TEVA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TEVA has a market cap of 18.7B. Regarding current trading prices, ZTS is priced at $150.90, while TEVA trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TEVA's P/E ratio is -14.18. In terms of profitability, ZTS's ROE is +0.51%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ZTS is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ITCI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZTS is priced at $150.90, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZTS's ROE is +0.51%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ZTS is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs NBIX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, NBIX has a market cap of 13B. Regarding current trading prices, ZTS is priced at $150.90, while NBIX trades at $133.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas NBIX's P/E ratio is 44.69. In terms of profitability, ZTS's ROE is +0.51%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ZTS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs RDY Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, RDY has a market cap of 12.1B. Regarding current trading prices, ZTS is priced at $150.90, while RDY trades at $14.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas RDY's P/E ratio is 18.43. In terms of profitability, ZTS's ROE is +0.51%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ZTS is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs CTLT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZTS is priced at $150.90, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZTS's ROE is +0.51%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ZTS is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs VTRS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, VTRS has a market cap of 10.4B. Regarding current trading prices, ZTS is priced at $150.90, while VTRS trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas VTRS's P/E ratio is -2.80. In terms of profitability, ZTS's ROE is +0.51%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ZTS is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ELAN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ELAN has a market cap of 7.3B. Regarding current trading prices, ZTS is priced at $150.90, while ELAN trades at $14.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ELAN's P/E ratio is 19.55. In terms of profitability, ZTS's ROE is +0.51%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ZTS is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs RGC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, RGC has a market cap of 7.1B. Regarding current trading prices, ZTS is priced at $150.90, while RGC trades at $13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas RGC's P/E ratio is -1440.00. In terms of profitability, ZTS's ROE is +0.51%, compared to RGC's ROE of -0.50%. Regarding short-term risk, ZTS is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LNTH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, ZTS is priced at $150.90, while LNTH trades at $72.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas LNTH's P/E ratio is 19.61. In terms of profitability, ZTS's ROE is +0.51%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZTS is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PRGO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, ZTS is priced at $150.90, while PRGO trades at $27.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas PRGO's P/E ratio is -22.45. In terms of profitability, ZTS's ROE is +0.51%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ZTS is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs AMRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, AMRX has a market cap of 3.7B. Regarding current trading prices, ZTS is priced at $150.90, while AMRX trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas AMRX's P/E ratio is -197.75. In terms of profitability, ZTS's ROE is +0.51%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, ZTS is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs HCM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, HCM has a market cap of 3.1B. Regarding current trading prices, ZTS is priced at $150.90, while HCM trades at $17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas HCM's P/E ratio is 88.70. In terms of profitability, ZTS's ROE is +0.51%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ALVOW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ALVOW has a market cap of 3.1B. Regarding current trading prices, ZTS is priced at $150.90, while ALVOW trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.51%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ZTS is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ALVO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ALVO has a market cap of 2.6B. Regarding current trading prices, ZTS is priced at $150.90, while ALVO trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ALVO's P/E ratio is 23.35. In terms of profitability, ZTS's ROE is +0.51%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ZTS is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs BHC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ZTS is priced at $150.90, while BHC trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas BHC's P/E ratio is -52.79. In terms of profitability, ZTS's ROE is +0.51%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DCPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZTS is priced at $150.90, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZTS's ROE is +0.51%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, ZTS is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs BGM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, BGM has a market cap of 2.1B. Regarding current trading prices, ZTS is priced at $150.90, while BGM trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas BGM's P/E ratio is -53.15. In terms of profitability, ZTS's ROE is +0.51%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ZTS is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs INDV Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, INDV has a market cap of 1.9B. Regarding current trading prices, ZTS is priced at $150.90, while INDV trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas INDV's P/E ratio is -312.00. In terms of profitability, ZTS's ROE is +0.51%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EMBCV Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZTS is priced at $150.90, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.51%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SUPN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, ZTS is priced at $150.90, while SUPN trades at $32.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SUPN's P/E ratio is 29.94. In terms of profitability, ZTS's ROE is +0.51%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ZTS is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TARO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $150.90, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZTS's ROE is +0.51%, compared to TARO's ROE of +0.02%. Regarding short-term risk, ZTS is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ANIP Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, ZTS is priced at $150.90, while ANIP trades at $66.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ANIP's P/E ratio is -55.43. In terms of profitability, ZTS's ROE is +0.51%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ZTS is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs HROW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ZTS is priced at $150.90, while HROW trades at $36.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas HROW's P/E ratio is -60.79. In terms of profitability, ZTS's ROE is +0.51%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DVAX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, ZTS is priced at $150.90, while DVAX trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas DVAX's P/E ratio is -21.88. In terms of profitability, ZTS's ROE is +0.51%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZTS is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EVO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, ZTS is priced at $150.90, while EVO trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas EVO's P/E ratio is -5.35. In terms of profitability, ZTS's ROE is +0.51%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ZTS is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs FLXN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, ZTS is priced at $150.90, while FLXN trades at $25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas FLXN's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.51%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, ZTS is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs PAHC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $150.90, while PAHC trades at $29.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas PAHC's P/E ratio is 37.36. In terms of profitability, ZTS's ROE is +0.51%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ZTS is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs AVDL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, AVDL has a market cap of 1.1B. Regarding current trading prices, ZTS is priced at $150.90, while AVDL trades at $11.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas AVDL's P/E ratio is -42.23. In terms of profitability, ZTS's ROE is +0.51%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PCRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, ZTS is priced at $150.90, while PCRX trades at $22.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas PCRX's P/E ratio is -9.90. In terms of profitability, ZTS's ROE is +0.51%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ZTS is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AMPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, AMPH has a market cap of 998.9M. Regarding current trading prices, ZTS is priced at $150.90, while AMPH trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas AMPH's P/E ratio is 7.68. In terms of profitability, ZTS's ROE is +0.51%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ZTS is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs COLL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, COLL has a market cap of 993.5M. Regarding current trading prices, ZTS is priced at $150.90, while COLL trades at $31.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas COLL's P/E ratio is 25.34. In terms of profitability, ZTS's ROE is +0.51%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ZTS is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PETQ Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZTS is priced at $150.90, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZTS's ROE is +0.51%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs CRON Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, CRON has a market cap of 805.5M. Regarding current trading prices, ZTS is priced at $150.90, while CRON trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas CRON's P/E ratio is 14.93. In terms of profitability, ZTS's ROE is +0.51%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TLRY Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TLRY has a market cap of 699.2M. Regarding current trading prices, ZTS is priced at $150.90, while TLRY trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TLRY's P/E ratio is -0.61. In terms of profitability, ZTS's ROE is +0.51%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ZTS is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EMBC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, EMBC has a market cap of 601.4M. Regarding current trading prices, ZTS is priced at $150.90, while EMBC trades at $10.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas EMBC's P/E ratio is 11.56. In terms of profitability, ZTS's ROE is +0.51%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EOLS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, EOLS has a market cap of 594.5M. Regarding current trading prices, ZTS is priced at $150.90, while EOLS trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas EOLS's P/E ratio is -10.36. In terms of profitability, ZTS's ROE is +0.51%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ZTS is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ORGO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ORGO has a market cap of 578.5M. Regarding current trading prices, ZTS is priced at $150.90, while ORGO trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ORGO's P/E ratio is -28.50. In terms of profitability, ZTS's ROE is +0.51%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ZTS is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BDSI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZTS is priced at $150.90, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZTS's ROE is +0.51%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZTS is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs SIGA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SIGA has a market cap of 489.4M. Regarding current trading prices, ZTS is priced at $150.90, while SIGA trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SIGA's P/E ratio is 10.22. In terms of profitability, ZTS's ROE is +0.51%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ZTS is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs KMDA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, KMDA has a market cap of 448.5M. Regarding current trading prices, ZTS is priced at $150.90, while KMDA trades at $7.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas KMDA's P/E ratio is 27.86. In terms of profitability, ZTS's ROE is +0.51%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ZTS is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs AQST Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, AQST has a market cap of 420.2M. Regarding current trading prices, ZTS is priced at $150.90, while AQST trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas AQST's P/E ratio is -7.29. In terms of profitability, ZTS's ROE is +0.51%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ZTS is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SNDL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SNDL has a market cap of 406.6M. Regarding current trading prices, ZTS is priced at $150.90, while SNDL trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SNDL's P/E ratio is -5.27. In terms of profitability, ZTS's ROE is +0.51%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ZTS is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EBS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, EBS has a market cap of 376.1M. Regarding current trading prices, ZTS is priced at $150.90, while EBS trades at $7.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas EBS's P/E ratio is -2.69. In terms of profitability, ZTS's ROE is +0.51%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ZTS is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ALIM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZTS is priced at $150.90, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZTS's ROE is +0.51%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, ZTS is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs LFCR Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, LFCR has a market cap of 276.2M. Regarding current trading prices, ZTS is priced at $150.90, while LFCR trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas LFCR's P/E ratio is -5.07. In terms of profitability, ZTS's ROE is +0.51%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ZTS is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ZYBT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ZYBT has a market cap of 269.7M. Regarding current trading prices, ZTS is priced at $150.90, while ZYBT trades at $5.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ZYBT's P/E ratio is 94.83. In terms of profitability, ZTS's ROE is +0.51%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ZTS is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ACB Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ACB has a market cap of 264.4M. Regarding current trading prices, ZTS is priced at $150.90, while ACB trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ACB's P/E ratio is 21.36. In terms of profitability, ZTS's ROE is +0.51%, compared to ACB's ROE of +0.00%. Regarding short-term risk, ZTS is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LNDC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZTS is priced at $150.90, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZTS's ROE is +0.51%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ZTS is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CGC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, CGC has a market cap of 232.6M. Regarding current trading prices, ZTS is priced at $150.90, while CGC trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas CGC's P/E ratio is -0.27. In terms of profitability, ZTS's ROE is +0.51%, compared to CGC's ROE of -1.13%. Regarding short-term risk, ZTS is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TYHT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZTS is priced at $150.90, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZTS's ROE is +0.51%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ZTS is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ESPR Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ESPR has a market cap of 227.9M. Regarding current trading prices, ZTS is priced at $150.90, while ESPR trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ESPR's P/E ratio is -1.35. In terms of profitability, ZTS's ROE is +0.51%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, ZTS is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TKNO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TKNO has a market cap of 219.6M. Regarding current trading prices, ZTS is priced at $150.90, while TKNO trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TKNO's P/E ratio is -9.34. In terms of profitability, ZTS's ROE is +0.51%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ZTS is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs OGI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, OGI has a market cap of 195.5M. Regarding current trading prices, ZTS is priced at $150.90, while OGI trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas OGI's P/E ratio is 11.23. In terms of profitability, ZTS's ROE is +0.51%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SXTC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SXTC has a market cap of 188.5M. Regarding current trading prices, ZTS is priced at $150.90, while SXTC trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SXTC's P/E ratio is 0.01. In terms of profitability, ZTS's ROE is +0.51%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ZTS is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs REPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZTS is priced at $150.90, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZTS's ROE is +0.51%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZTS is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DERM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, DERM has a market cap of 167.5M. Regarding current trading prices, ZTS is priced at $150.90, while DERM trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas DERM's P/E ratio is -19.43. In terms of profitability, ZTS's ROE is +0.51%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ZTS is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs BIOA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, BIOA has a market cap of 164.9M. Regarding current trading prices, ZTS is priced at $150.90, while BIOA trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas BIOA's P/E ratio is -2.32. In terms of profitability, ZTS's ROE is +0.51%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ZTS is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs THTX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, THTX has a market cap of 144.4M. Regarding current trading prices, ZTS is priced at $150.90, while THTX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas THTX's P/E ratio is -16.53. In terms of profitability, ZTS's ROE is +0.51%, compared to THTX's ROE of +0.38%. Regarding short-term risk, ZTS is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs IRWD Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, IRWD has a market cap of 123.5M. Regarding current trading prices, ZTS is priced at $150.90, while IRWD trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas IRWD's P/E ratio is -4.02. In terms of profitability, ZTS's ROE is +0.51%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, ZTS is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SCTL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZTS is priced at $150.90, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZTS's ROE is +0.51%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZTS is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs PROC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ZTS is priced at $150.90, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZTS's ROE is +0.51%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZTS is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs CRDL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, CRDL has a market cap of 100.8M. Regarding current trading prices, ZTS is priced at $150.90, while CRDL trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas CRDL's P/E ratio is -3.59. In terms of profitability, ZTS's ROE is +0.51%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, ZTS is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs OPTN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZTS is priced at $150.90, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZTS's ROE is +0.51%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ZTS is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ZOM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZTS is priced at $150.90, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZTS's ROE is +0.51%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ZTS is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs GRVI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZTS is priced at $150.90, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZTS's ROE is +0.51%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, ZTS is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs IXHL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, IXHL has a market cap of 76.8M. Regarding current trading prices, ZTS is priced at $150.90, while IXHL trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas IXHL's P/E ratio is -0.67. In terms of profitability, ZTS's ROE is +0.51%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, ZTS is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs INCR Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, INCR has a market cap of 74.5M. Regarding current trading prices, ZTS is priced at $150.90, while INCR trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas INCR's P/E ratio is -3.67. In terms of profitability, ZTS's ROE is +0.51%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ZYNE Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ZTS is priced at $150.90, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ZTS's ROE is +0.51%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ZTS is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs QNTM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, QNTM has a market cap of 68.9M. Regarding current trading prices, ZTS is priced at $150.90, while QNTM trades at $22.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas QNTM's P/E ratio is -1.79. In terms of profitability, ZTS's ROE is +0.51%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ZTS is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SSIC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZTS is priced at $150.90, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZTS's ROE is +0.51%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, ZTS is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ASRT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ASRT has a market cap of 66.6M. Regarding current trading prices, ZTS is priced at $150.90, while ASRT trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ASRT's P/E ratio is -2.17. In terms of profitability, ZTS's ROE is +0.51%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ZTS is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs VLNS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZTS is priced at $150.90, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZTS's ROE is +0.51%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZTS is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CPIX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, CPIX has a market cap of 52.4M. Regarding current trading prices, ZTS is priced at $150.90, while CPIX trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas CPIX's P/E ratio is -14.58. In terms of profitability, ZTS's ROE is +0.51%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ZTS is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs JUPW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZTS is priced at $150.90, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZTS's ROE is +0.51%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ZTS is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs QLI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZTS is priced at $150.90, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZTS's ROE is +0.51%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZTS is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs RMTI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, RMTI has a market cap of 38.3M. Regarding current trading prices, ZTS is priced at $150.90, while RMTI trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas RMTI's P/E ratio is -112.00. In terms of profitability, ZTS's ROE is +0.51%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs KALA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, KALA has a market cap of 36.8M. Regarding current trading prices, ZTS is priced at $150.90, while KALA trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas KALA's P/E ratio is -0.77. In terms of profitability, ZTS's ROE is +0.51%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ZTS is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EGRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, EGRX has a market cap of 32.4M. Regarding current trading prices, ZTS is priced at $150.90, while EGRX trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas EGRX's P/E ratio is 2.94. In terms of profitability, ZTS's ROE is +0.51%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ZTS is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs HEXO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZTS is priced at $150.90, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZTS's ROE is +0.51%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZTS is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SCYX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, SCYX has a market cap of 27.8M. Regarding current trading prices, ZTS is priced at $150.90, while SCYX trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas SCYX's P/E ratio is -1.27. In terms of profitability, ZTS's ROE is +0.51%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ZTS is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs CYTH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZTS is priced at $150.90, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZTS's ROE is +0.51%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ZTS is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs DRRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, DRRX has a market cap of 17.5M. Regarding current trading prices, ZTS is priced at $150.90, while DRRX trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas DRRX's P/E ratio is -1.18. In terms of profitability, ZTS's ROE is +0.51%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ZTS is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs GELS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, GELS has a market cap of 17.3M. Regarding current trading prices, ZTS is priced at $150.90, while GELS trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas GELS's P/E ratio is -7.63. In terms of profitability, ZTS's ROE is +0.51%, compared to GELS's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PRPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, PRPH has a market cap of 16.7M. Regarding current trading prices, ZTS is priced at $150.90, while PRPH trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas PRPH's P/E ratio is -0.18. In terms of profitability, ZTS's ROE is +0.51%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, ZTS is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs FLGC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, FLGC has a market cap of 14.6M. Regarding current trading prices, ZTS is priced at $150.90, while FLGC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas FLGC's P/E ratio is -0.67. In terms of profitability, ZTS's ROE is +0.51%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ZTS is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AYTU Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, AYTU has a market cap of 14.6M. Regarding current trading prices, ZTS is priced at $150.90, while AYTU trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas AYTU's P/E ratio is -1.59. In terms of profitability, ZTS's ROE is +0.51%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ACRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZTS is priced at $150.90, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZTS's ROE is +0.51%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ZTS is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs COSM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, COSM has a market cap of 14M. Regarding current trading prices, ZTS is priced at $150.90, while COSM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas COSM's P/E ratio is -0.44. In terms of profitability, ZTS's ROE is +0.51%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ZTS is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TXMD Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TXMD has a market cap of 13.4M. Regarding current trading prices, ZTS is priced at $150.90, while TXMD trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TXMD's P/E ratio is -6.11. In terms of profitability, ZTS's ROE is +0.51%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ZTS is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AGRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZTS is priced at $150.90, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZTS's ROE is +0.51%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, ZTS is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs IMCC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, IMCC has a market cap of 9.4M. Regarding current trading prices, ZTS is priced at $150.90, while IMCC trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas IMCC's P/E ratio is -2.19. In terms of profitability, ZTS's ROE is +0.51%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, ZTS is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TLPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, TLPH has a market cap of 8.7M. Regarding current trading prices, ZTS is priced at $150.90, while TLPH trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas TLPH's P/E ratio is -0.96. In terms of profitability, ZTS's ROE is +0.51%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ZTS is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs YCBD Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, YCBD has a market cap of 8.5M. Regarding current trading prices, ZTS is priced at $150.90, while YCBD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas YCBD's P/E ratio is 0.01. In terms of profitability, ZTS's ROE is +0.51%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BFRI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, BFRI has a market cap of 8.2M. Regarding current trading prices, ZTS is priced at $150.90, while BFRI trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas BFRI's P/E ratio is -1.07. In terms of profitability, ZTS's ROE is +0.51%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, ZTS is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs NLTX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZTS is priced at $150.90, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZTS's ROE is +0.51%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, ZTS is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LCI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZTS is priced at $150.90, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZTS's ROE is +0.51%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZTS is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BGXX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 65.6B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ZTS is priced at $150.90, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 26.41, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ZTS's ROE is +0.51%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, ZTS is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.